Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Key facts

Sponsor

SWOG Cancer Research Network

Principal Investigator

Vassiliki Papadimitrakopoulou

SWOG Cancer Research Network

Intervention

Laboratory Biomarker Analysis(other)

Enrollment

51 enrolled

Eligibility

All sexes

Timeline

2017 – 2021

Study locations (30)

• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
• Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
• University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States
• Yuma Cancer Center, Yuma, Arizona, United States
• CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ataxia-telangiectasia variant

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07224308
  Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mm
  The Levine Center for Plastic Surgery
• ACTIVE NOT RECRUITINGPHASE2NCT06033092
  Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
  European Institute of Oncology
• ACTIVE NOT RECRUITINGPHASE2NCT04030559
  Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
  Marc Dall'Era, MD
• RECRUITINGNCT05129605
  Prostate Cancer Genetic Risk Evaluation and Screening Study
  Massachusetts General Hospital

See all trials for Ataxia-telangiectasia variant →